Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04891289 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
A Phase 2 study of Intrahepatic Cholangiocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 11
- Study locations
NCT04891289 is a Phase 2 study of Intrahepatic Cholangiocarcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 164 participants, above the 126-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (30% higher). The trial reports 11 study locations across 6 states.
The verdict
NCT04891289, a Phase 2 study of Intrahepatic Cholangiocarcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 11
- Study locations
Study Summary
This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The researchers want to find out whether the study treatment works better than the standard chemotherapy to delay progression of disease. For the study treatment to be considered better than the standard treatment, the study treatment should increase the time until progression of disease by an average of 3 months, compared with the usual approach.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Dexamethasone
- DRUG Gemcitabine
- DRUG Floxuridine (FUDR)
- DEVICE Implanted Medical Device
Study Locations (11)
New York
- Memorial Sloan Kettering Commack - Limited Protocol Activities - Commack
- Memorial Sloan Kettering Westchester - Limited Protocol Activities - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Limited Protocol Activities - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities - Basking Ridge
- Memorial Sloan Kettering Monmouth - Limited Protocol Activities - Middletown
- Memorial Sloan Kettering Bergen - Limited Protocol Activities - Montvale
Maryland
- National Heart, Lung, and Blood Institute (NIH) (Data Collection Only) - Bethesda
Missouri
- Washington University (Data Collection Only) - St Louis
North Carolina
- Duke University (Data Collection Only) - Durham
Other
- Erasmus University (Data Collection Only) - Rotterdam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04891289
The ClinicalTrials.gov registry entry for NCT04891289 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 126-participant average among 17 other Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (30% higher). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intrahepatic Cholangiocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Oxaliplatin is the first listed.
NCT04891289 reports 11 study locations spanning 6 distinct geographic areas - top geographies include New York, New Jersey, Maryland.
Frequently Asked Questions
What is clinical trial NCT04891289 about?
NCT04891289 is a clinical study titled "Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery". This study will compare the safety and effects of HAI floxuridine and dexamethasone combined with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The researchers want to fin...
What is the current status of trial NCT04891289?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2021-05-07. Estimated completion is 2026-05.
What conditions does trial NCT04891289 study?
This clinical trial studies the following conditions: Intrahepatic Cholangiocarcinoma.
What interventions are being tested in trial NCT04891289?
The interventions under investigation include: Oxaliplatin (DRUG), Dexamethasone (DRUG), Gemcitabine (DRUG), Floxuridine (FUDR) (DRUG), Implanted Medical Device (DEVICE).
Who is sponsoring clinical trial NCT04891289?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04891289 being conducted?
This trial has 11 study locations across Maryland, Missouri, New Jersey, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intrahepatic Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
RECRUITING · Phase 2
-
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 2
-
Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy
RECRUITING · Phase 2
-
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.